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Introduction
Antipolymyositis/scleroderma (PM/Scl) autoantibodies
are often detected in sera of patients with idiopathic
inflammatory myopathies (IIM), scleroderma, and the
PM/Scl overlap syndrome, although some anti-PM/Scl-
positive patients may not have either of these syndromes
[1–4]. The antigenic complex recognized by the PM/Scl
autoantibodies has been reported to consist of 11 to 16
proteins, with molecular weights ranging from 20 to 110
kDa found in SDS–PAGE [5,6].
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The autoantigenic polymyositis/scleroderma (PM/Scl) complex was recently shown to be the human
homologue of the yeast exosome, which is an RNA-processing complex. Our aim was to assess
whether, in addition to targeting the known autoantigens PM/Scl-100 and PM/Scl-75, autoantibodies
also target recently identified components of the PM/Scl complex. The prevalence of autoantibodies
directed to six novel human exosome components (hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p,
hCsl4p) was determined in sera from patients with idiopathic inflammatory myopathy (n = 48),
scleroderma (n = 11), or the PM/Scl overlap syndrome (n = 10). The sera were analyzed by enzyme-
linked immunosorbent assays and western blotting using the affinity-purified recombinant proteins. Our
results show that each human exosome component is recognized by autoantibodies. The hRrp4p and
hRrp42p components were most frequently targeted. The presence of autoantibodies directed to the
novel components of the human exosome was correlated with the presence of the anti-PM/Scl-100
autoantibody in the sera of patients with idiopathic inflammatory myopathy (IIM), as was previously
found for the anti-PM/Scl-75 autoantibody. Other clear associations between autoantibody activities
were not found. These results further support the conception that the autoimmune response may
initially be directed to PM/Scl-100, whereas intermolecular epitope spreading may have caused the
autoantibody response directed to the associated components.
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Most anti-PM/Scl-positive sera are reactive with a
100–110 kDa protein, while some also recognize a
75–80 kDa protein [5–7]. Complementary DNA cloning of
both autoantigens revealed that the major one is a
polypeptide of 100 kDa (referred to as PM/Scl-100) [8,9]
and that the 75–80 kDa one (referred to as PM/Scl-75) is
a 39 kDa acidic polypeptide that migrates aberrantly in
SDS–PAGE [10].
Recently, it was discovered that the PM/Scl-100 and -75
autoantigens are related to the Escherichia coli exoribonu-
cleases D and PH, respectively [11]. The nucleolar localiza-
tion of the PM/Scl complex suggested a role in ribosome
synthesis [12], and, indeed, it was found that the yeast
homologue of PM/Scl-100, Rrp6p, is involved in the matura-
tion of 5.8S ribosomal RNA [13]. Moreover, a yeast complex,
named the exosome, consisting of 11 3′ → 5′ exoribonucle-
ases, including Rrp45p (the yeast homologue of PM/Scl-75)
and Rrp6p, has been characterized [14–16]. In yeast, the
exosome was shown to degrade or process RNA species in
the nucleus as well as in the cytoplasm [15,17–20].
In human cells, a complex similar in size to the yeast
exosome has been shown to contain both the PM/Scl
autoantigens and the human homologue of the yeast
exosome component Rrp4p [14]. This finding indicates
that the human PM/Scl complex is related to the yeast
exosome, and it is therefore referred to as the human
exosome (reviewed in [21]). Recently, cDNAs encoding
three novel components of the human exosome (hRrp40p,
hRrp41p, and hRrp46p) were isolated and were shown to
be associated with the PM/Scl-100 autoantigen and
hRrp4p [22]. Furthermore, cDNAs encoding four addi-
tional human proteins with homology to yeast exosome
components have been isolated, although conclusive evi-
dence for their physical association with the PM/Scl
complex is still lacking [4,23–25].
Our aim in this study was to assess whether autoantibod-
ies target other components of the human exosome than
the PM/Scl-100 and PM/Scl-75 autoantigens.
Materials and methods
Patients
The prevalence of autoantibodies directed to six novel
components of the human exosome (hRrp4p, hRrp40p,
hRrp41p, hRrp42p, hRrp46p, hCsl4p) was determined in
sera from anti-PM/Scl-positive patients with idiopathic
inflammatory myopathy (IIM, n = 48), scleroderma
(n = 11), or the myositis/scleroderma overlap syndrome
(n = 10). The patients with IIM were diagnosed according
to previously published criteria [26,27] and most of these
sera were included in a previous cohort study assessing
the prevalence of several autoantibody types, including
those directed to PM/Scl-100 and PM/Scl-75, in a large
group of European patients with myositis [28]. Patients
with sclerodactyly or systemic sclerosis according to pre-
viously published criteria [29] were diagnosed as having
scleroderma myositis/scleroderma overlap syndrome if
they also fulfilled the myositis criteria for polymyositis
(n = 4) or dermatomyositis (n = 6).
Expression and purification of recombinant proteins
The recombinant proteins were produced in E. coli BL21
(DE3) pLysS as His-tagged (hRrp4p, hRrp40p, hRrp41p,
hRrp46p) or gluthatione-S-transferase (GST)-tagged
(hCsl4p and hRrp42p) fusion proteins. The expression
constructs of hRrp4p, hRrp42p, and hCsl4p were gener-
ously provided by Dr D Tollervey. The hRrp40p, hRrp41p,
and hRrp46p expression constructs as well as the expres-
sion and affinity purification procedures have been
described previously [22].
Enzyme-linked immunosorbent assay
Per well, approximately 25 ng of each of the purified anti-
gens (hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p,
and hCsl4p) diluted in 100 µl buffer A (35 mM NaHCO3,
15 mM Na2CO3, pH 9.6) was coated to 96-well poly-
styrene microtiter Greiner plates overnight at 4°C. ELISA
plates were washed three times with 200 µl of buffer B
(PBS/0.05% (v/v) Tween-20) before nonspecific sites
were blocked with 150 µl of 0.1% bovine serum albumin in
buffer A for 2 hours at room temperature. Plates were
washed and to each well was added 50 µl of the serum
samples, which were diluted 1:200 in buffer C (0.3% (w/v)
BSA, 150 mM NaCl, 10 mM Tris–HCl pH7.6, 1% (v/v)
Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v)
sodium dodecyl sulfate). The plates were incubated for
1 hour at room temperature. They were then washed five
times and 50 µl rabbit antihuman peroxidase-conjugated
antibody (anti-IgG, IgA, IgM, kappa, lambda (P-212;
DAKO, Glostrup, Denmark) diluted 1:1000 in buffer C was
added and incubated for 1 hour at room temperature. After
five rounds of washing, bound antibodies were visualized
with 100 µl 3,3′,5,5′-tetramethylbenzidine (TMB; Sigma,
Zwijdrecht, The Netherlands) using standard methods. The
enzyme reaction was stopped after 10 min at room temper-
ature by adding 100 µl of 2-M H2SO4 and the absorbance
was measured at 450 nm. All sera were tested at least in
duplicate in parallel with positive and negative controls on
each ELISA plate. The cutoff value was defined as three
times the mean absorbance obtained from a pool of 10
normal human sera, which was run on each ELISA plate.
Results
Prevalence of autoantibodies directed to novel
exosome components
The presence of autoantibodies directed to hRrp4p,
hRrp40p, hRrp41p, hRrp42p, hRrp46p, and hCsl4p was
determined by ELISA using purified recombinant proteins,
which were produced in E. coli either as His-tagged or as
GST-tagged fusion proteins.
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Table 1 summarizes the ELISA data on the antiexosome
reactivity of the selected groups of patient sera. In total,
63% (n = 30) of the IIM sera, 73% (n = 8) of the sclero-
derma sera, and 60% (n = 6) of the myositis/scleroderma
overlap sera contained autoantibodies directed to one or
more of the novel components of the human exosome.
Our results further show that each exosome component is
recognized by autoantibodies, although some are prefer-
entially targeted. The hRrp4p component is most fre-
quently recognized by the anti-PM/Scl-positive IIM sera
(25/48; 52%), the scleroderma sera (7/11; 64%), and
myositis/scleroderma overlap sera (6/10; 60%). Also the
hRrp42p component is frequently recognized, albeit less
often than hRrp4p (20–36%). Fig. 1 shows the ELISA
readings of the antiexosome-positive sera after correction
for background signals.
Sera that were positive in ELISA were also tested for reac-
tivity with the recombinant exosome components by
western blotting. The results indicated that some novel
components are poor autoantigens on western blot. Using
this approach, we could confirm the reactivity of 75%
(3/4) of anti-hRrp40p-positive sera, 71% (12/17) of anti-
hRrp42p-positive sera, and 29% (11/38) of anti-hRrp4p-
positive sera. However, some sera that were strongly
positive on ELISA did not react with the same antigen on
immunoblots, while other sera that were only weakly posi-
tive on ELISA reacted well on immunoblots. These results
suggest that both linear and nonlinear epitopes are impor-
tant for recognition.
Antiexosome autoantibodies are mostly restricted to
anti-PM/Scl-100-positive sera
The previously reported dominance of the anti-PM/Scl-
100 autoantibody activity in anti-PM/Scl-positive sera was
Table 1
Reactivity of autoimmune patient sera with components of the human exosome
Exosome component IIM [no. (%)] Myositis/scleroderma overlap syndrome [no. (%)] Scleroderma [no. (%)]
Total number analyzed 48 10 11
PM/Scl-100a 45 (94) 10 (100) 11 (100)
PM/Scl-75a 26 (54) 9 (90) 7 (64)
hRrp4pb 25 (52) 6 (60) 7 (64)
hRrp40pb 3 (6) 1 (10) 0
hRrp41pb 5 (10) 0 0
hRrp42pb 11 (23) 2 (20) 4 (36)
hRrp46pb 6 (13) 0 0
hCsl4pb 7 (15) 0 0
Total reactivity with novel components 30 (63) 6 (60) 8 (73)
aAnti-PM/Scl-100 and anti-PM/Scl-75 reactivity of IIM sera was previously analyzed [28]. bNovel human exosome components analyzed in this
study. IIM = idiopathic inflammatory myopathies; PM/Scl = polymyositis/scleroderma.
Figure 1
Antiexosome ELISA data obtained with sera from anti-PM/Scl-positive
patients. Sera from patients with IIM, scleroderma, and
myositis/scleroderma overlap were analyzed by ELISA for reactivity
with six novel components of the human exosome (hRrp4p, hRrp40p,
hRrp41p, hRrp42p, hRrp46p, and hCsl4p). A pool of 10 normal
human sera was run on each ELISA plate to determine the absorbance
cutoff value, which was set at three times the absorbance of this
negative control. The figure shows all positive ELISA signals corrected
for background by subtracting the cutoff value for each individual
ELISA plate. The corrected ELISA signals of anti-PM/Scl-positive IIM
sera (open squares), scleroderma sera (circles) and
myositis/scleroderma overlap syndrome sera (filled squares) are
indicated. OD450 = optical density at λ450 nm.












also apparent in the sera analyzed in this study. None of
the scleroderma or myositis/scleroderma overlap sera and
only three IIM sera contained anti-PM/Scl-75 autoantibod-
ies without detectable anti-PM/Scl-100 reactivity. To
determine whether the autoantibody response directed to
any of the six novel exosome components is correlated
with an anti-PM/Scl-100 response, we also analyzed a
large group of anti-PM/Scl-100-negative IIM sera
(n = 168) by ELISA (data not shown). These results indi-
cated that some, predominantly weak, reactivities may be
present in anti-PM/Scl-negative sera: 5% (8/168) of the
sera contained detectable reactivity with one or more
novel exosome components. In contrast, as mentioned
above, 63% of anti-PM/Scl-positive IIM sera contained
such reactivity.
We also tried to discover other correlations between anti-
exosome autoantibodies. Although the number of anti-
hRrp4p-positive sera is comparable to the number of
anti-PM/Scl-75-positive sera, the presence of the two types
of autoantibody does not appear to be correlated. Further-
more, most of the sera analyzed in this study recognized
only one (25/44 positive sera) or two (12/44 positive sera)
of the novel exosome components (Table 2). As might be
expected, the single reactivity was predominantly directed
to hRrp4p (20/25 sera) and the most frequently encoun-
tered combination was anti-hRrp4p with anti-hRrp42p reac-
tivity (8/12 sera). Few sera (n = 7) contained reactivity with
more than two novel components of the exosome.
Discussion
In this study we examined the prevalence of autoantibod-
ies directed to six novel components of the human
exosome in sera of patients diagnosed with IIM, sclero-
derma, or PM/Scl overlap syndrome. Compared with other
published series of patients with anti-PM/Scl autoantibod-
ies [2,3], in our cohort, fewer patients with scleroderma or
PM/Scl overlap than with IIM were available. This does not
impair the conclusions drawn from our data, because the
autoantibody subspecificities detected were very similar
for the three groups of patients.
Our results show that the anti-human-exosome autoanti-
body response is not restricted to the previously identi-
fied autoantigenic components PM/Scl-100 and
PM/Scl-75. Indeed, all the novel exosome components
analyzed were targeted by some autoantibodies, albeit
with relatively low frequencies in some cases. These
autoantibodies are associated predominantly with the
anti-PM/Scl-100 response, as has been found for anti-
PM/Scl-75 autoantibodies [5–7]. This correlation may be
particularly interesting in the cases of hRrp42p and
hCsl4p, whose association with the human exosome
complex has not yet been unequivocally established
[14,23]. Our results support the idea that the initial
autoimmune response may be directed to the PM/Scl-
100 protein and that subsequent intermolecular epitope
spreading may play a role in the generation of autoanti-
bodies directed to other components of the exosome
components. A similar mechanism has been suggested
to generate anti-tRNAHis autoantibodies in anti-Jo-1-posi-
tive IIM patients or anti-U1A, anti-U1C, anti-U1-70K, or
anti-Sm autoantibodies in anti-U1 small nuclear RNP-
positive SLE patients [30,31]. The event that initiates the
autoantibody response is unknown, but we can specu-
late that modification of the PM/Scl-100 autoantigen
occurring in dying cells, for example by granzyme-B-
induced cleavage, could generate neoepitopes that
trigger the aberrant immune response in genetically sus-
ceptible individuals [32,33].
On the other hand, there is also a possibility that the
intact exosome complex is exposed to the immune
system, triggering a selective immune response to some
of the components. The immunogenicity of the exosome
components may be different for each patient and may be
defined by phenomena yet unknown. In that case, the
autoantibodies directed to different components might be
evoked simultaneously. Since none of the patients
studied has been followed up over a long period, it is not
possible to predict which of the described scenarios
(epitope spreading versus simultaneous immunization)
may actually be occurring.
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Table 2
Number of novel components of the human exosome targeted by the serum of patients with idiopathic inflammatory myopathy
(IIM), scleroderma, or the polymyositis/scleroderma (PM/Scl) overlap syndrome
Number of targeted components per seruma
Number of reactive serab 1 2 3 4 5 6
IIM (n = 48) 30 16 8 3 1 1 1
Scleroderma (n = 11) 8 5 3 0 0 0 0
Myositis/scleroderma overlap (n = 10) 6 4 1 1 0 0 0
aFor these calculations, only the novel exosome components (hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p, and hCsl4p) were taken into
account. bTotal number of sera reactive with at least one of the novel components analyzed.
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Conclusion
The PM/Scl complex, or human exosome, is targeted by
autoantibodies that are directed not only to the known
autoantigens PM/Scl-100 and PM/Scl-75 but also to
recently identified exosome components, most frequently
hRrp4p and hRrp42p. However, the anti-PM/Scl-100
reactivity remains the most important one in these sera,
supporting the idea that the autoimmune response may
initially be directed to this protein.
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